Can patients achieve sufficient peak inspiratory flow rate (PIFR) with Turbuhaler® during acute exacerbation of asthma?

References

• GINA. 2022. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2022. Available from: www.ginasthma.org.
   Google Scholar
• IPH. 2011. National Health and Morbidity Survey (NHMS) 2011 (NMRR-10-757-6837) Volume III: Healthcare Demand and Out-of-Pocket Health Expenditure.
   Google Scholar
• Bateman ED, Reddel HK, O'Byrne PM, Barnes PJ, Zhong N, Keen C, Jorup C, Lamarca R, Siwek-Posluszna A, FitzGerald JM. As-needed budesonide–formoterol versus maintenance budesonide in mild asthma. N Engl J Med. 2018;378(20):1877–1887. doi:10.1056/NEJMoa1715275.
   PubMed Web of Science ®Google Scholar
• O'Byrne PM, FitzGerald JM, Bateman ED, Barnes PJ, Zhong N, Keen C, Jorup C, Lamarca R, Ivanov S, Reddel HK. Inhaled combined budesonide–formoterol as needed in mild asthma. N Engl J Med. 2018;378(20):1865–1876. doi:10.1056/NEJMoa1715274.
   PubMed Web of Science ®Google Scholar
• Sobieraj DM, Weeda ER, Nguyen E, Coleman CI, Michael White C, Lazarus SC, Blake K. v, Lang JE, Baker WL. Association of inhaled corticosteroids and long-acting β-agonists as controller and quick relief therapy with exacerbations and symptom control in persistent asthma a systematic review and meta-analysis. JAMA - J Am Med Assoc. 2018;319(14):1485–1496.
   PubMed Web of Science ®Google Scholar
• Crossingham I, Turner S, Ramakrishnan S, Fries A, Gowell M, Yasmin F, Richardson R, Webb P, O'Boyle E, Hinks TSC. Combination fixed-dose β agonist and steroid inhaler as required for adults or children with mild asthma: a Cochrane systematic review. BMJ Evid Based Med. 2022;27(3):178–184. doi:10.1136/bmjebm-2021-111764.
   PubMedGoogle Scholar
• Buddiga P. 2020. Use of metered dose inhalers, spacers, and nebulizers: practice essentials, overview, preparation. Available from: https://emedicine.medscape.com/article/1413366-overview#a2.
   Google Scholar
• Usmani OS. Choosing the right inhaler for your asthma or COPD patient. Ther Clin Risk Manag. 2019;15:461–472. doi:10.2147/TCRM.S160365.
   PubMed Web of Science ®Google Scholar
• Laube BL, Janssens HM, de Jongh FH, Devadason SG, Dhand R, Diot P, Everard ML, Horvath I, Navalesi P, Voshaar T, et al. 2011. What the pulmonary specialist should know about the new inhalation therapies. Eur Respir J. 2011;37:1308–1331.
   Google Scholar
• Lavorini F, Fontana GA, Usmani OS. New inhaler devices-the good, the bad and the ugly. Respiration. 2014;88(1):3–15. doi:10.1159/000363390.
   PubMed Web of Science ®Google Scholar
• Levy ML, Carroll W, Izquierdo Alonso JL, Keller C, Lavorini F, Lehtimäki L. Understanding dry powder inhalers: key technical and patient preference attributes. Adv Ther. 2019;36(10):2547–2557. doi:10.1007/s12325-019-01066-6.
   PubMed Web of Science ®Google Scholar
• Lavorini F, Magnan A, Christophe J, Voshaar T, Corbetta L, Broeders M, Dekhuijzen R, Sanchis J, Viejo JL, Barnes P, et al. Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD. Repir Med. 2008;102:593–604.
   PubMed Web of Science ®Google Scholar
• Everard ML, Devadason SG, Le Souëf PN. Flow early in the inspiratory manoeuvre affects the aerosol particle size distribution from a Turbuhaler. Respir Med. 1997;91(10):624–628. doi:10.1016/s0954-6111(97)90009-3.
   PubMed Web of Science ®Google Scholar
• Newman S, Busse WW. Evolution of dry powder inhaler design, formulation, and performance. Respir Med. 2002;96(5):293–304.
   PubMed Web of Science ®Google Scholar
• Price DB, Román-Rodríguez M, McQueen RB, Bosnic-Anticevich S, Carter V, Gruffydd-Jones K, Haughney J, Henrichsen S, Hutton C, Infantino A, et al. Inhaler errors in the CRITIKAL study: type, frequency, and association with asthma outcomes. J Allergy Clin Immunol Pract. 2017;5(4):1071–1081.
   PubMed Web of Science ®Google Scholar
• Decramer M, Lacquet LM, Fagard R, Rogiers P. Corticosteroids contribute to muscle weakness in chronic airflow obstruction. Am J Respir Crit Care Med. 1994;150(1):11–16. doi:10.1164/ajrccm.150.1.8025735.
   PubMed Web of Science ®Google Scholar
• Broeders MEAC, Molema J, Hop WCJ, Vermue NA, Folgering, H, TM. The course of inhalation profiles during an exacerbation of obstructive lung disease. Respir Med. 2004;98(12):1173–1179. doi:10.1016/j.rmed.2004.04.010.
   PubMed Web of Science ®Google Scholar
• Borgstrom L, Bondesson E, Moren F, Trofast E, Newman SP. Lung deposition of budesonide inhaled via Turbuhaler®: a comparison with terbutaline sulphate in normal subjects. Eur Respir J. 1994;7(1):69–73. doi:10.1183/09031936.94.07010069.
   PubMed Web of Science ®Google Scholar
• De Boer AH, Gjaltema D, Hagedoorn P. Inhalation characteristics and their effects on in vitro drug delivery from dry powder inhalers Part 2: effect of peak flow rate (PIFR) and inspiration time on the in vitro drug release from three different types of commercial dry powder inhalers. 1996;138(1):45–56. Int J Pharm. 1996;138(1):45–56.
   Google Scholar
• Hill LS, Slater AL. A comparison of the performance of two modern multidose dry powder asthma inhalers. Respir Med. 1998;92(1):105–110. doi:10.1016/s0954-6111(98)90040-3.
   PubMed Web of Science ®Google Scholar
• Janssens W, VandenBrande P, Hardeman E, de Langhe E, Philps T, Troosters T, Decramer M. Inspiratory flow rates at different levels of resistance in elderly COPD patients. Eur Respir J. 2008;31(1):78–83. doi:10.1183/09031936.00024807.
   PubMed Web of Science ®Google Scholar
• Mahler DA. Peak inspiratory flow rate as a criterion for dry powder inhaler use in chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2017;14(7):1103–1107. doi:10.1513/AnnalsATS.201702-156PS.
   PubMed Web of Science ®Google Scholar
• Newman SP, Morén F, Trofast E, Talaee N, Clarke SW. Terbutaline sulphate turbuhaler: effect of inhaled flow rate on drug deposition and efficacy. Int J Pharm. 1991;74(2-3):209–213. doi:10.1016/0378-5173(91)90239-K.
   Google Scholar
• Ghosh S, Ohar JA, Drummond MB. Peak inspiratory flow rate in chronic obstructive pulmonary disease: implications for dry powder inhalers. J Aerosol Med Pulm Drug Deliv. 2017;30(6):381–387. doi:10.1089/jamp.2017.1416.
   PubMed Web of Science ®Google Scholar
• Haidl P, Heindl S, Siemon K, Bernacka M, Cloes RM. Inhalation device requirements for patients’ inhalation maneuvers. Respir Med. 2016;118:65–75. doi:10.1016/j.rmed.2016.07.013.
   PubMed Web of Science ®Google Scholar
• Sanders MJ. Guiding inspiratory flow: development of the in-check DIAL G16, a tool for improving inhaler technique. Pulmon Med. 2017;2017:1–7. doi:10.1155/2017/1495867.
   Web of Science ®Google Scholar
• Haughney J, Lee AJ, McKnight E, Pertsovskaya I, O’Driscoll M, Usmani OS. Peak inspiratory flow measured at different inhaler resistances in patients with asthma. J Allergy Clin Immunol Pract. 2020;9(2):890–896.
   PubMed Web of Science ®Google Scholar
• Brown PH, Ning ACWS, Greening AP, McLean A, Crompton GK. Peak inspiratory flow through Turbuhaler® in acute asthma. Eur Respir J. 1995;8(11):1940–1941.
   PubMed Web of Science ®Google Scholar
• Naing L, Winn T, Rusli BN. Practical issues in calculating the sample size for prevalence studies. Arch Orofac Sci. 2006;1(Ci):9–14.
   Google Scholar